Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Opening Session Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Jun
09
Today In Oncology
GLP-1 RAs May Reduce Risk of Obesity-Related Cancers
Daraxonrasib Nearly Doubles Survival in Previously Treated Metastatic Pancreatic Cancer
Teclistamab in Previously Treated Multiple Myeloma
Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer
Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo